A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants

• Sign the informed consent form and be able to complete the research as required.
• Age and weight meet the requirements.
• During the screening, the results of physical examination, vital signs, laboratory tests, electrocardiogram, etc. are normal or have no clinical significance(healthy individuals).
• Take effective contraceptive measures as required.
• During the screening, HBsAg, HBV DNA, ALT, and HBeAg meet certain indicators (CHB participants).

Exclusion Criteria:

• Have a serious systemic disease or a history of malignant tumor.
• Have other liver diseases besides chronic HBV infection, or have liver dysfunction, significant liver fibrosis/ cirrhosis, history of liver cell carcinoma or suspected cases.
• Have autoimmune diseases or diseases with a risk of immune activation.
• Have a questionable allergy to the test drugs and their components, or have an allergic constitution.
• Participate in other clinical trials or receive investigational drug treatment within the specified time before screening, and have received related drug
• Have received solid organ transplantation or hematopoietic stem cell transplantation before screening.
• Have acute infection, major trauma or major surgery with clinical significance that has not fully recovered within the specified time before screening, or have a surgical plan during the study.
• Have abnormal laboratory tests, vital signs or electrocardiogram results during screening and have clinical significance as judged by the researcher.
• Have positive screening for related infectious diseases.
• Have a history of drug abuse or alcoholism; or have a large amount of smoking before screening and cannot stop during the study.
• Have consumed caffeine, xanthine-containing foods or beverages, or engaged in intense exercise within the specified time before administration, or have been unable to stop during the study.
• Have positive urine drug screening or alcohol breath test during screening; have donated blood or lost a large amount of blood before screening, received blood transfusion, or have a blood donation plan during the study.
• Have a positive pregnancy test during screening.
• Abnormal skin at the injection site.
• Have a history of fainting or hemisomnia, difficulty in blood collection, or inability to tolerate venipuncture blood collection.
• The researcher considers that there are other factors that make one unsuitable to participate in this trial.